Cochrane Review Questions Anti-Amyloid Alzheimer's Drug Efficacy
Analysis based on 7 articles · First reported Apr 16, 2026 · Last updated Apr 17, 2026
The Cochrane review's findings are likely to negatively impact the stock prices of pharmaceutical companies like Eli Lilly and Company, Biogen, and Eisai, which produce anti-amyloid drugs. It could also lead to a re-evaluation of public funding and regulatory approvals for these treatments in various nations.
A major review by the Cochrane, considered a gold standard in evidence analysis, concluded that anti-amyloid drugs like Lecanemab and Donanemab, once hailed as breakthroughs for Alzheimer's disease, do not provide clinically meaningful benefits to patients. The review combined data from 17 clinical trials involving over 20,000 people. While brain scans confirmed the drugs successfully removed amyloid plaques, this did not translate into tangible improvements for patients, challenging the long-held amyloid hypothesis. This finding has prompted caution, with countries like the United Kingdom and France already refusing to cover these costly drugs due to concerns about effectiveness and side effects. Some experts, including John Hardy (neuroscientist), criticized the review's methodology for combining data from newer and older drugs, potentially skewing results. However, the review's authors, Francesco Nonino and Edo Richard, maintain their findings refute the idea that amyloid removal alone benefits patients, suggesting future research should explore other causes of Alzheimer's.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard